グリオーマのゲノム・エピゲノム異常

Genomic and Epigenomic Abnormalities in Gliomas

Point

・グリオーマの発生にはさまざまなゲノム・エピゲノムの異常が関与している．

・ゲノム・エピゲノム異常には診断マーカーや予後因子，予測因子として有用なものも多く含まれる．

　Advances in genetic and epigenetic analyses and immunohistochemical studies involving the development of mutation-specific or histone-methylated antibodies have provided many significant findings about gliomas. Based on these findings, the WHO developed and published the classification of tumors of the central nervous system in 2016. In the classification system, molecular information was combined with pathological findings. After its publication, the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official WHO（cIMAPCT-NOW）was published to evaluate and recommend changes to future central nervous system tumor classifications. This review describes the genetic and epigenetic features of gliomas, mainly those associated with the WHO classification and cIMPACT-NOW.